New enzyme-linked immunosorbent digoxin assay on the ADVIA IMS 800i system is virtually free from interference of endogenous digoxin-like immunoreactive factors.
Endogenous digoxin-like immunoreactive factors (DLIF) may crossreact with antidigoxin antibody and falsely elevate immunoassay results. Recently, a new enzyme-linked immunosorbent chemiluminescent assay for digoxin has been available for use on the ADVIA IMS (Integrated Modular System) 800i analyzer (Bayer Diagnostics). We studied potential interference of DLIF with this new digoxin assay. We analyzed 30 serum specimens from patients who have pathologic conditions that may increase serum DLIF concentrations. These patients were never exposed to digoxin or other agents that may lead to a measurable digoxin concentration. We also analyzed 10 specimens from neonates, 10 cord blood specimens, and 10 amniotic fluid specimens. Apparent digoxin concentrations were measured using the new enzyme-linked immunosorbent digoxin assay (IMS-Digoxin), a fluorescence polarization immunoassay (FPIA), and also a chemiluminescent immunoassay (CLIA, run on ACS:180(R) system from Bayer Diagnostics). We observed measurable apparent digoxin levels with the FPIA in 4 uremic patients (range 0.21-0.36 ng/mL, digoxin equivalent), 7 patients with liver disease (range 0.21-0.72 ng/mL), and 3 patients in the third trimester of pregnancy (0.22-0.66 ng/mL). We also observed measurable DLIF concentrations with the FPIA in 2 neonates (0.22 and 0.36 ng/mL), 5 cord blood specimens (range 0.21-1.18 ng/mL), and 5 amniotic fluid specimens (0.21-0.50 ng/mL). None of these DLIF-positive specimens showed any measurable digoxin concentration using the IMS-Digoxin or the CLIA assay. When serum specimens containing elevated concentrations of DLIF but no digoxin (as measured by FPIA) were supplemented with known concentrations of digoxin, we observed falsely elevated digoxin concentrations, as expected, only by the FPIA. In contrast, we observed a good agreement between the target and observed concentrations when the new IMS-Digoxin or the CLIA assay was used. We conclude that the IMS-Digoxin assay is free from interference of DLIF.
Dasgupta
Amitava
A
Department of Pathology and Laboratory Medicine, University of Texas Houston Medical School, 6431 Fannin, MSB 2.292, Houston, TX 77030, USA. Amitava.Dasgupta@uth.tmc.edu
Kang
Edward
E
Datta
Pradip
P
D000328:Adult; D000653:Amniotic Fluid / Q000737:chemistry; D002298:Cardenolides / Q000097:blood* / Q000276:immunology*; D003951:Diagnostic Errors; D004076:Digoxigenin / Q000008:administration & dosage / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods* / Q000592:standards / Q000639:trends*; D005189:False Positive Reactions; D005260:Female; D005312:Fetal Blood / Q000737:chemistry; D016231:Fluorescence Polarization Immunoassay / Q000379:methods; D006801:Humans; D007231:Infant, Newborn / Q000097:blood; D008107:Liver Diseases / Q000097:blood; D008163:Luminescent Measurements / Q000379:methods / Q000592:standards / Q000639:trends; D011247:Pregnancy; D011263:Pregnancy Trimester, Third / Q000097:blood; D012015:Reference Standards; D012503:Saponins / Q000097:blood* / Q000276:immunology*; D044967:Serum / Q000737:chemistry; D014511:Uremia / Q000097:blood
D002298:Cardenolides; D012503:Saponins; C034504:digoxin-like factors; D004076:Digoxigenin